Financhill
Sell
36

NKTR Quote, Financials, Valuation and Earnings

Last price:
$0.94
Seasonality move :
-1.1%
Day range:
$0.92 - $1.00
52-week range:
$0.63 - $1.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.01x
P/B ratio:
3.52x
Volume:
1.2M
Avg. volume:
2.5M
1-year change:
35.1%
Market cap:
$172M
Revenue:
$90.1M
EPS (TTM):
-$0.84

Analysts' Opinion

  • Consensus Rating
    Nektar Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $4.56, Nektar Therapeutics has an estimated upside of 389.17% from its current price of $0.93.
  • Price Target Downside
    According to analysts, the lowest downside price target is $1.30 representing 100% downside risk from its current price of $0.93.

Fair Value

  • According to the consensus of 5 analysts, Nektar Therapeutics has 389.17% upside to fair value with a price target of $4.56 per share.

NKTR vs. S&P 500

  • Over the past 5 trading days, Nektar Therapeutics has overperformed the S&P 500 by 6.3% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Nektar Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Nektar Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nektar Therapeutics reported revenues of $24.1M.

Earnings Growth

  • Nektar Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nektar Therapeutics reported earnings per share of -$0.18.
Enterprise value:
-72.5M
EV / Invested capital:
--
Price / LTM sales:
2.01x
EV / EBIT:
--
EV / Revenue:
-0.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$63.1M
Return On Assets:
-44.58%
Net Income Margin (TTM):
-180.7%
Return On Equity:
-154.23%
Return On Invested Capital:
-154.23%
Operating Margin:
-142.18%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $95M $88.3M $93.1M $24.1M $24.1M
Gross Profit $73.5M $55.5M $63.1M $11.7M $19.7M
Operating Income -$312.3M -$145.5M -$135.9M -$33.5M -$34.3M
EBITDA -$411M -$255.7M -$137.8M -$38.3M -$30M
Diluted EPS -$2.44 -$1.56 -$0.84 -$0.24 -$0.18
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $1B $986.1M $599.5M $399M $286.5M
Total Assets $1.5B $1.3B $781M $442.2M $308M
Current Liabilities $126.5M $140M $84M $52.1M $67.6M
Total Liabilities $337.7M $475.7M $368.8M $282.9M $259.1M
Total Equity $1.2B $801.5M $412.2M $159.4M $48.9M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$397.8M -$203.3M -$176.6M -$42.1M -$43.9M
Cash From Investing $446M $162.2M $99.7M $56.4M $46.1M
Cash From Financing $4M $121K $42M -- $13K
Free Cash Flow -$408.9M -$204.4M -$177.8M -$42.2M -$44.6M
NKTR
Sector
Market Cap
$172M
$43.6M
Price % of 52-Week High
48.35%
47.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
35.1%
-34.6%
Beta (5-Year)
0.576
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $0.90
200-day SMA
Sell
Level $1.21
Bollinger Bands (100)
Sell
Level 0.88 - 1.28
Chaikin Money Flow
Sell
Level -14.1M
20-day SMA
Buy
Level $0.84
Relative Strength Index (RSI14)
Buy
Level 53.83
ADX Line
Buy
Level 27.9
Williams %R
Neutral
Level -34.3721
50-day SMA
Buy
Level $0.92
MACD (12, 26)
Sell
Level 0.01
25-day Aroon Oscillator
Buy
Level 12
On Balance Volume
Sell
Level -106.4M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-12.999)
Sell
CA Score (Annual)
Level (-2.6774)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2802)
Sell
Piotroski F Score (Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Stock Forecast FAQ

In the current month, NKTR has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NKTR average analyst price target in the past 3 months is $4.56.

  • Where Will Nektar Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Nektar Therapeutics share price will rise to $4.56 per share over the next 12 months.

  • What Do Analysts Say About Nektar Therapeutics?

    Analysts are divided on their view about Nektar Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nektar Therapeutics is a Sell and believe this share price will drop from its current level to $1.30.

  • What Is Nektar Therapeutics's Price Target?

    The price target for Nektar Therapeutics over the next 1-year time period is forecast to be $4.56 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is NKTR A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Nektar Therapeutics is a Hold. 3 of 5 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of NKTR?

    You can purchase shares of Nektar Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nektar Therapeutics shares.

  • What Is The Nektar Therapeutics Share Price Today?

    Nektar Therapeutics was last trading at $0.94 per share. This represents the most recent stock quote for Nektar Therapeutics. Yesterday, Nektar Therapeutics closed at $0.93 per share.

  • How To Buy Nektar Therapeutics Stock Online?

    In order to purchase Nektar Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will AMD Beat the S&P 500?
Will AMD Beat the S&P 500?

High-performance and adaptive computing leader Advanced Micro Devices (NASDAQ:AMD) is…

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock